NRXPNRx Pharmaceuticals, Inc.
The schedule
- Thu15Oct
Expected binary clinical or regulatory update regarding the NRX-101 and HTX-100 development pathways.
- Fri12Feb
Q3 financial print evaluating operational burn rate versus clinical trial execution.
- Fri14May
Full-year 2026 financials and strategic outlook for the 2027 commercial/regulatory pathway.
- Fri13Aug
First-quarter update evaluating cash bleed and early commercialization or late-stage trial milestones.
Past
- Fri14Aug
Actual outcome: Mixed
NRx Pharmaceuticals reported a Q2 loss of $0.18 per share, missing consensus estimates, alongside a revenue miss. However, this financial underperformance was offset by positive regulatory news earlier in the week, as the FDA completed its first-cycle review of the company's preservative-free ketamine ANDA with no major drug-related deficiencies. The competing impacts of near-term financial struggles and promising pipeline advancements left the stock's price action flat.
Quarterly earnings report with a critical focus on liquidity, capital raising, and pipeline updates.